**MINUTES**

**CPIC CONFERENCE CALL**

DATE: August 1, 2019

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| Housekeeping Announcements | Attendance will be taken by poll after each conference call. Members will receive an email with a doodle link after each call. Please enter your first and last name and check the box indicating you were in attendance. No action required if you were unable to make the conference call. | Kelly will send the poll link. |
| Guidelines in progress | Guideline updates in progress:   * *CYP2C9/HLA/*phenytoin: Drafting recommendation * *CYP2D6*/opioid: evidence review underway * *CYP2C19/*clopidogrel: authorship plan underway   New guidelines in progress:   * *CYP2C19/*PPIs: Drafting recommendation * *CYP2C9/*celecoxib: Drafting guideline * *mtRNR1*/aminoglycosides: authorship plan underway | Guideline preparation will continue and Kelly will continue to follow-up. If you or someone you know has expertise in *mtRNR1*/aminoglycosides and would like to be nominated for the writing committee for this CPIC guideline, please email Kelly ([Kelly.caudle@stjude.org](mailto:Kelly.caudle@stjude.org)). |
| Impact of CYP2D6 genotype to phenotype changes on CPIC guidelines | Currently, there are inconsistencies in the translation of *CYP2D6* genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating *CYP2D6* genotype to phenotype among a panel of international CYP2D6 experts (<https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/>). Modifications to CPIC’s current system include downgrading *CYP2D6\*10* activity value to 0.25 and changing the phenotype assigned to activity score of 1 from normal metabolizer to intermediate metabolizer.  As a result, the following changes will be made to the *CYP2D6* genotype to phenotype table:  1) Activity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer;  2) Activity score of 2.25 (duplicated normal function alleles in combination with CYP2D6\*10 (e.g.,CYP2D6\*1x2/\*10, CYP2D6\*2x2/\*10)) changed from CYP2D6 ultrarapid metabolizer to CYP2D6 normal metabolizer;  3) All activity scores for diplotypes containing a *CYP2D6\*10* allele have been updated accordingly (i.e. activity scores changed to reflect activity value of 0.25).  We have submitted the paper for this project and it is in review. If/when accepted, CPIC will make changes to the guideline pages on the CPIC website (<https://cpicpgx.org/guidelines/>). Kelly is working with guideline authors to make any necessary updates to the current published recommendations. | Kelly will continue to update. |
| Open discussion re: FDA and PGx testing | Members discussed concerns and updates regarding the FDA’s recent actions regarding PGx testing (see attached slides for overview of FDA’s actions). CPIC leadership has calls with representatives from the FDA on a regular basis and will have a call next week to discuss some of these concerns. A lot of our members have expressed a desire to convene with others with similar concerns and actively work to understand and respond to the FDA on this topic. | If you are interested in convening to discuss the FDA’s recent actions, please email Kelly Caudle (Kelly.caudle@stjude.org). |